Hôpital de La Tour Partners with Solu to Enhance Genomic Surveillance in Switzerland

MEYRIN, Switzerland - Solu, a genomics company based in Helsinki, Finland, has partnered with Hôpital de La Tour, a leading healthcare institution in Geneva. Through this 6-month collaboration, Hôpital de La Tour will implement Solu's genomic surveillance technology to improve its infectious disease monitoring, antimicrobial resistance tracking and outbreak prevention efforts.

Through this partnership, Hôpital de La Tour will get access to Solu's expertise in next-generation sequencing and real-time bioinformatics, together establishing a state-of-the-art genomic surveillance program. This program will enable the hospital to rapidly identify and track the emergence of new pathogens, antimicrobial resistance, and other threats to public health.

"We are delighted to partner with Solu to test their genomic surveillance technology. We expect that this collaboration provides our healthcare teams with real-time and actionable data. Solu could enhance our ability to detect and respond quicker to potential infectious disease threats. It represents a promising step in refining our prevention workflows and furthering our commitment to patient safety." mentions Axelle Alibert, Chief Quality Officer at Hôpital de La Tour.

Solu's technology will be integrated into Hôpital de La Tour's existing diagnostic workflows, allowing for the seamless collection and analysis of genomic data from microbial samples. This real-time information will empower the hospital's medical teams to make more informed decisions, implement targeted interventions, and collaborate with regional and global health authorities to improve overall preparedness.

“We are excited to collaborate with Hôpital de La Tour, a leading healthcare institution known for its innovative approaches,” said Sam Sihvonen, CEO of Solu. “Through this partnership, we will showcase how genomic surveillance can significantly improve public health and strengthen healthcare systems.”

The Solu-Hôpital de La Tour collaboration is expected to serve as a model for other healthcare providers seeking to access advanced genomic technologies to combat emerging health threats.

More information

Sam Sihvonen, CEO & Co-founder of Solu

sam@solugenomics.com